| Name | Title | Contact Details |
|---|---|---|
Peter Vladimirov |
Chief Technology Officer | Profile |
Penn State Health Milton S. Hershey Medical Center, Penn State College of Medicine and The Children`s Hospital at Penn State Health Milton S. Hershey Medical Center are committed to enhancing the quality of life through improved health, the professional preparation of those who will serve the health needs of others, and the discovery of knowledge that will benefit all.
Holmusk is a data science and health technology company dedicated to establishing objective evidence as a core utility to the treatment of mental health and chronic diseases. Founded in 2015, Holmusk is headquartered in Singapore with offices in North Carolina, New York City, London, Malaysia and Shanghai. Holmusk was recognized as a Technology Pioneer in 2019 by the World Economic Forum and is part of the Innovations in Healthcare’s 2020 Innovator Cohort. Holmusk`s vision is to build the world`s largest Real-World Evidence (RWE) platform and enable a leapfrog-change in research and the provision of care through machine learning, deep learning and digital tools. Holmusk’s proprietary technology is harnessed to analyze real-world data and drive data-driven medicine.
Cybertech Medical is a La Verne, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Robin Medical is a Pikesville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kedrion Biopharma develops and produces plasma-derived therapies, making them available to meet patients` needs the world over. We collect and fractionate blood plasma for the development, production and distribution of plasma derivatives used in the treatment of patients suffering from rare and chronic conditions such as hemophilia and immune system deficiencies. A corporation is not a person, but a corporation is run by people and it affects people. And Kedrion`s business is people. The very nature of our enterprise is to help people live more full and healthy lives. This commitment extends to how we conduct our business, that is, in ways that are consistent with our mission: to build bridges that.benefit people. Long a major player in the plasma derivatives sector in Italy, as partner with the Italian Health System, Kedrion has now become an international participant in the industry with a market presence in about 100 countries. We have plants in Italy, Hungary and the United States and plasma collection centers in the U.S., Germany and Hungary. Kedrion looks forward to continued expansion and the wider sharing of its experience, know-how and technology to foster self-sufficiency of plasma-derived therapies worldwide and to bring healthier and less restricted lives to people suffering from rare disorders. Kedrion Biopharma produces wealth for investors, employees and for the local community, consistent with its own vision and values: responsibility, transparency, confidence in and respect for people. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion Biopharma builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.